P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

May 2009

Features

Health Care and Law

When Can Patients Sue Drug Companies?

Supreme Court Finds That FDA Approval Does Not Stand In the Way

In the recent case of Wyeth v. Levine, the drug company unsuccessfully appealed an award to a patient who had been harmed by Phenergan—even though the FDA had approved this injectable drug. Dr. Field reviews this precedent-setting case.
Robert I. Field, JD, MPH, PhD

Commentary

Stimulus Bill Promises a New Era In Digital Health Care

But American Recovery and Reinvestment Act Gives Pharmacies Short Shrift

The advent of electronic prescribing was supposed to be a large part of the cure for improving patient outcomes and reducing prescription errors, but only a fraction of scripts are being sent electronically. Independent and hospital pharmacies continue to lag behind the technology wave because of the expense involved.
Stephen Barlas

H.P. Acthar Gel and Cosyntropin Review

Clinical and Financial Implications

Although H.P. Acthar Gel has been beneficial in MS, spasms, and adrenal testing, its high cost has led to a larger role for alternatives like cosyntropin and steroids.
Jacob Gettig, PharmD, MPH, BCPS; Joseph P. Cummings, PhD; and Karl Matuszewski, MS, PharmD

Meeting Highlights

American College of Cardiology, 58th Annual Scientific Session

Summaries include clinical trials involving statins; eptifibatide; non-statins (Zetia); and a "polypill" containing antihypertensive agents, a statin, and aspirin (PolyCap).
Walter Alexander

Pharmaceutical Approval Update

Topics include Afinitor for renal cell carcinoma; Ixiaro vaccine to prevent Japanese encephalitis; and ATryn, an antithrombin product engineered from goats.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

Double Decade Drivers

David B. Nash, MD, MBA, discusses how an arcane system of pricing determines which medications end up on formularies and how benchmarks to establish best practices can reduce drug costs.
David B. Nash, MD, MBA

Medication Errors

For Best Quality, Send Only Original Orders to Pharmacies

Matthew Grissinger, RPh, FASCP, provides instructions on the correct use of document-imaging technology in sending prescriptions to pharmacies.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Spotlight Shines Once Again on Medicaid Payments to Pharmacies

Report and Lawsuit Settlement Might Lead to New Formula

Stephen Barlas discusses the differences between Medicaid and Medicare Part D in their dispensing fees to pharmacies for generic drugs.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Afinitor (everolimus) to Raptiva (efalizumab), P&T presents the latest information about FDA approvals, new indications, and recalls.

Drug Forecast

Rivaroxaban (Xarelto) for the Prevention of Thromboembolic Disease

An Inside Look at the Oral Direct Factor Xa Inhibitor

The authors review rivaroxaban (Xarelto), an anti-coagulant for preventing thromboembolic disease.
Younos Abdulsattar, PharmD Candidate, Rahul Bhambri, PharmD Candidate, and Anna Nogid, BS, PharmD, BCPS